Reaction
Henoch-Schonlein Purpura reporting signals
As of the last recalculation, Henoch-Schonlein Purpura appears in 2,143 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-AATY (PRR 21.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Aaty | 102 | 21.9 | 22.0 |
| Adalimumab-Fkjp | 99 | 21.7 | 21.8 |
| Adalimumab-Adaz | 99 | 19.1 | 19.1 |
| Cefepime | 20 | 13.7 | 13.7 |
| Cefepime Hydrochloride | 21 | 12.8 | 12.8 |
| Pyrazinamide | 12 | 12.5 | 12.5 |
| Isoniazid | 20 | 12.1 | 12.1 |
| Ciprofolxacin | 85 | 12.0 | 12.0 |
| Ciprofloxacin Tablets | 85 | 12.0 | 12.0 |
| Rifampin | 17 | 11.4 | 11.4 |
| Vancomycin | 61 | 10.5 | 10.5 |
| Vancomycin Hydrochloride | 65 | 9.8 | 9.9 |
| Ciprofloxacin Hydrochloride | 93 | 9.7 | 9.7 |
| Rifampicin | 10 | 9.6 | 9.6 |
| Ciprofloxacin | 86 | 9.4 | 9.4 |
| Infliximab | 190 | 9.2 | 9.2 |
| Minocycline | 10 | 8.4 | 8.4 |
| Daspone | 8 | 8.0 | 8.0 |
| Dapsone Gel, 5% | 8 | 8.0 | 8.0 |
| Gefitinib | 7 | 7.6 | 7.6 |
| Dapsone | 8 | 7.3 | 7.3 |
| Iohexol | 6 | 7.0 | 7.0 |
| Sotalol Hydrochloride | 12 | 7.0 | 7.0 |
| Piperacillin And Tazobactam | 9 | 6.9 | 6.9 |
| Ceftriaxone | 21 | 6.3 | 6.3 |
| Levofloxacin | 38 | 6.2 | 6.2 |
| Levofloxacin In 5% Dextrose | 38 | 6.2 | 6.2 |
| Ceftriaxone Sodium | 24 | 6.1 | 6.1 |
| Durvalumab | 11 | 5.3 | 5.3 |
| Ifosfamide | 11 | 5.0 | 5.0 |
| Ado-Trastuzumab Emtansine | 4 | 4.6 | 4.6 |
| Erlotinib Hydrochloride | 5 | 3.9 | 3.9 |
| Pembrolizumab | 37 | 3.5 | 3.5 |
| Isotretinoin | 16 | 3.2 | 3.2 |
| Dornase Alfa | 4 | 2.0 | 2.0 |
| Bimekizumab | 4 | 1.8 | 1.8 |
| Osimertinib | 6 | 1.8 | 1.8 |
| Droxidopa | 3 | 1.4 | 1.4 |